3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to

Jennifer L Whitwell1, Scott A Przybelski, Stephen D Weigand

  • 1Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.

Insights

Mild cognitive impairment (MCI) shows early brain atrophy in medial temporal lobes at least 3 years before Alzheimer's disease (AD) diagnosis. This grey matter loss progresses over time, potentially predicting AD onset in aMCI patients.

Area of Science:

  • Neuroscience
  • Radiology

Background:

  • Mild cognitive impairment (MCI), especially amnestic MCI (aMCI), is a transitional stage to Alzheimer's disease (AD).
  • Understanding the progression of brain changes in aMCI is crucial for early detection and intervention in prodromal AD.

Purpose of the Study:

  • To assess the progression of cerebral atrophy in individuals with aMCI over time, from the aMCI stage to the diagnosis of AD.
  • To correlate patterns of grey matter loss with the Braak and Braak staging of AD pathology.

Main Methods:

  • Longitudinal study of 33 aMCI subjects with three serial MRI scans (approx. 3 years before AD, 1 year before AD, and at AD diagnosis).
  • Comparison with 33 age- and gender-matched healthy controls.
  • Voxel-based morphometry (VBM) used to analyze grey matter atrophy patterns, employing customized templates to minimize bias.

Main Results:

  • At least 3 years before AD diagnosis, aMCI subjects showed grey matter loss primarily in medial temporal lobes (amygdala, hippocampus, entorhinal cortex) and fusiform gyrus.
  • By 1 year before AD diagnosis, atrophy extended to middle temporal gyrus, posterior hippocampus, and involved the parietal lobe.
  • At AD diagnosis, atrophy was widespread, affecting medial temporal lobes, temporoparietal association cortices, and frontal lobes, consistent with Braak staging.

Conclusions:

  • Grey matter atrophy in aMCI begins in the medial temporal lobe and fusiform gyrus at least 3 years prior to clinical AD diagnosis.
  • The observed pattern and progression of atrophy align with the Braak and Braak pathological staging of AD.
  • Serial MRI-based 3D grey matter atrophy patterns may serve as a predictive marker for the time to AD diagnosis in aMCI subjects.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.